Receptor Monoclonal Antibodies that Inhibit Tumor Angiogenesis
Abstract
The survival and growth of solid tumors is dependent on the neo-vascularization of the growing tumor mass. Prior to the vascularization of a tumor, a subpopulation of tumor cells acquire an angiogenic phenotype characterized by the production of polypeptide growth factors that stimulate endothelial cell proliferation, migration and differentiation. By activating cell surface receptor molecules, these tumor-derived angiogenic factors induce the growth of blood vessels into the tumor from pre-existing blood vessels. Thus, the process of tumor angiogenesis represents an attractive target for the development of new cancer therapeutic agents. We are characterizing the signaling pathways utilized by vascular endothelial growth factor (VEGF), an angiogenic factor that is widely expressed by breast tumors, and we are generating neutralizing monoclonal antibodies to receptor molecules for VEGF. We will test the antibodies for the ability to block VEGF-induced endothelial cell proliferation and capillary growth in vitro.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2000
- Accession Number
- ADA389599
Entities
People
- J. D. Sato
Organizations
- American Type Culture Collection